Bruker vs Insulet
Bruker (BRKR), health care, and Insulet (PODD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Insulet is worth $10.1B on the stock market and Bruker $9.4B: Insulet is valued at 8% more. Bruker's operating margin in its latest fiscal year was 1.98% and Insulet's 17.5%. Over the past year Bruker's share price has moved +42.1% and Insulet's -56.4%.
Key facts
- Bruker market value
- $9.4B
- Insulet market value
- $10.1B
- Insulet P/E
- 23.7
- Bruker revenue
- $3.4BFY to 2025-12-31
- Insulet revenue
- $2.7BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Bruker | Insulet |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $9.4Blower | $10.1Bhigher |
| Revenue | $3.4Bhigher | $2.7Blower |
| Earnings | -$8.6Mlower | $247.1Mhigher |
| Employees | 11,085higher | 5,400lower |
| Total assets | $6.2Bhigher | $3.2Blower |
| Valuation | ||
| P/E | — | 23.7 |
| P/S | 2.7lower | 3.7higher |
| P/B | 4.1lower | 6.4higher |
| Dividend yield | 0.08%higher | 0.00%lower |
| Profitability | ||
| Operating margin | 1.98%lower | 17.5%higher |
| Balance sheet | ||
| Net assets | $2.5Bhigher | $1.5Blower |
| Total liabilities | $3.7Bhigher | $1.7Blower |
| Total debt | $1.9Bhigher | $949.2Mlower |
| Cash on hand | $298.8Mlower | $716.1Mhigher |
| Price change | ||
| Today | +1.22%higher | +0.03%lower |
| 1 year | +42.1%higher | -56.4%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Percentages are each holding's share of that investor's reported portfolio. Who owns BRKR · Who owns PODD
More on Bruker
Further comparisons
Bruker against its closest peers
Insulet against its closest peers
Learn
Questions and answers
Which is bigger, Bruker or Insulet?
By market value, Insulet is the larger: $10.1B against $9.4B for Bruker. By revenue in its latest fiscal year, Bruker is the larger: $3.4B against $2.7B for Insulet.
Which has the higher operating margin?
Insulet: 17.5%, against 1.98% for Bruker. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Bruker: 0.08%, against 0.00% for Insulet. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Bruker: $1.9B, against $949.2M for Insulet. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Bruker and Insulet?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Bruker and 1 holds Insulet.
Cite this page
Funkfolio, “Bruker vs Insulet”, data as of 17 November 2026. https://funkfolio.com/compare/brkr-vs-podd
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.